Acme United
Acme United's revenue rose 1.1% to $196 million in fiscal 2025. Its operating margin was 7.5%, up from 7.3% a year earlier. Free cash flow was $8 million, up 57.0%. It paid out $2 million in dividends and buybacks, 31% of free cash flow. The diluted share count fell 0.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Acme United does
Acme United makes and sells first aid and medical products and cutting tools. Its main products are first aid kits and medical supplies, scissors, shears, knives and sharpening tools. They are used in schools, homes, offices, hardware and sporting goods stores and industry.
It sells mainly to mass market and online retailers, industrial distributors, stationery distributors, office supply superstores, sporting goods stores and hardware chains, and also directly to consumers on its own websites. Net sales in 2025 were $196.5 million, and first aid and medical products are about 66% of total sales. Two customers each accounted for about 13% of net sales.
The company has operations in the United States, Canada, Germany, Hong Kong and China. It buys most of its products from suppliers outside the United States, mainly in Asia, and assembles first aid kits at plants in North America. It names Honeywell and Cintas as main competitors in first aid and safety, and 3M and Fiskars in cutting. It had 649 employees at the end of 2025.
Its biggest risks, as it describes them
- Losing a major customer, since two customers each account for a large share of its sales.
- Tariffs on goods it imports, mostly from Asia, and rising costs it cannot always pass on in prices.
- Trouble getting products to customers on time through shipping and fulfillment delays.
- Difficulty forecasting sales and orders, which depend on demand it cannot easily predict.
- It may need to raise more money to run the business.
Income statement
From fiscal 2016 to 2025, earnings per share grew 4.7% a year and net income 6.3% a year, as new shares raised the share count by 14% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 5 | 6 | 5 | 6 | 4 |
| Debt incl. finance leases | 33 | 50 | 13 | 18 | 12 |
| Net debt (negative means net cash) | 28 | 44 | 8 | 11 | 8 |
| Net debt to EBITDA | 1.7x | 4.0x | 0.5x | 0.6x | 0.4x |
| Debt to equity | 0.4x | 0.6x | 0.1x | 0.2x | 0.1x |
| Interest coverage | 13.8x | 2.6x | 4.3x | 6.8x | 8.8x |
| Current ratio | 4.7x | 4.8x | 3.5x | 4.2x | 4.2x |
| Quick ratio | 2.1x | 1.9x | 1.4x | 1.7x | 1.6x |
Cash flow
Projections
Project Acme United's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Acme United says to expect
- Annual savings from closing the DMT plant in 2027
The annual savings from the closure are expected to be more than $1.0 million in 2027.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Acme United shares on the open market, and 3 insiders sold $1.7 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Brian S OlschanPresident and COO, Director | Sold | 7,308 | $61.48 | $449,312 | Form 4 |
| Aug 13, 2026 | Brian BarkerDirector | Sold | 3,821 | $60.50 | $231,170 | Form 4 |
| Aug 12, 2026 | Brian S OlschanPresident and COO, Director | Sold | 339 | $58.39 | $19,794 | Form 4 |
| Aug 11, 2026 | Brian S OlschanPresident and COO, Director | Sold | 159 | $57.99 | $9,220 | Form 4 |
| Aug 10, 2026 | Brian S OlschanPresident and COO, Director | Sold | 5,304 | $57.07 | $302,699 | Form 4 |
| Aug 10, 2026 | Rex Lynn DavidsonDirector | Sold | 3,684 | $56.48 | $208,072 | Form 4 |
| Aug 7, 2026 | Brian S OlschanPresident and COO, Director | Sold | 125 | $55.72 | $6,965 | Form 4 |
| Aug 5, 2026 | Brian S OlschanPresident and COO, Director | Sold | 4,000 | $55.51 | $222,040 | Form 4 |
| Aug 4, 2026 | Brian S OlschanPresident and COO, Director | Sold | 981 | $56.75 | $55,672 | Form 4 |
| Aug 3, 2026 | Brian S OlschanPresident and COO, Director | Sold | 1 | $58.00 | $58 | Form 4 |
| May 28, 2026 | Brian S OlschanPresident and COO, Director | Sold | 4,833 | $42.00 | $202,986 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 7 of 9 | 6 of 9 | 7 of 9 |
| Rule of 40 | 11.4% | 4.0% | 4.9% |
| Altman Z'' | 7.39 | 7.46 | 7.65 |
| Accruals ratio | −7.1% | −1.2% | −4.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Pass | Fail | Pass |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 7 of 9 | 6 of 9 | 7 of 9 |
Compare
Put Acme United side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Acme United | FY25 | 1.1% | 7.5% | 3.9% | 9.4% | 0.4x | 7 | |
| Kewaunee Scientific | FY26 | 17.3% | 5.9% | 5.2% | 14.3% | 0.5x | 4 | Compare |
| Interface | FY25 | 5.4% | 11.8% | 8.8% | 19.0% | 0.6x | 7 | Compare |
| ACCO Brands | FY25 | −8.5% | 6.0% | — | 5.6% | 4.7x | 7 | Compare |
| MSA Safety | FY25 | 3.7% | 19.8% | 15.8% | 17.3% | 0.9x | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 125 | 131 | 137 | 142 | 164 | 182 | 194 | 192 | 194 | 196 |
| Revenue growth | 13.4% | 4.8% | 5.2% | 3.7% | 15.1% | 11.0% | 6.5% | −1.3% | 1.6% | 1.1% |
| Gross profit | 46 | 48 | 51 | 52 | 60 | 65 | 64 | 72 | 76 | 77 |
| Research and development | 1 | 1 | 1 | 1 | 0 | — | — | — | — | — |
| Operating income | 8 | 8 | 8 | 8 | 11 | 13 | 6 | 13 | 14 | 15 |
| Net income | 6 | 4 | 5 | 6 | 8 | 14 | 3 | 18 | 10 | 10 |
| Diluted EPS (US$) | 1.64 | 1.09 | 1.30 | 1.60 | 2.31 | 3.45 | 0.82 | 4.86 | 2.45 | 2.49 |
| Diluted shares (millions) | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Cash flow | ||||||||||
| Cash from operations | 9 | 5 | 4 | 15 | 6 | 5 | 3 | 29 | 12 | 18 |
| Capital expenditure | 2 | 3 | 3 | 2 | 3 | 6 | 4 | 5 | 7 | 11 |
| Free cash flow | 7 | 2 | 2 | 13 | 3 | −1 | −1 | 24 | 5 | 8 |
| Dividends paid | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Share buybacks | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Acquisitions | 7 | 7 | 0 | 0 | 0 | 0 | 10 | 1 | 1 | 2 |
| Stock-based compensation | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 6 | 9 | 4 | 7 | 4 | 5 | 6 | 5 | 6 | 4 |
| Debt incl. finance leases | 33 | 44 | 40 | 33 | 39 | 33 | 50 | 13 | 18 | 12 |
| Total assets | 92 | 115 | 110 | 111 | 130 | 144 | 164 | 149 | 162 | 171 |
| Total liabilities | 46 | 65 | 57 | 55 | 67 | 67 | 85 | 51 | 55 | 53 |
| Shareholders' equity | 46 | 50 | 52 | 56 | 63 | 77 | 79 | 98 | 107 | 118 |
| Margins and ratios | ||||||||||
| Gross margin | 36.6% | 36.7% | 36.9% | 36.5% | 36.3% | 35.6% | 32.8% | 37.7% | 39.3% | 39.4% |
| Operating margin | 6.8% | 6.0% | 5.4% | 5.9% | 7.0% | 7.0% | 3.2% | 6.9% | 7.3% | 7.5% |
| Net margin | 4.7% | 3.1% | 3.4% | 3.9% | 4.9% | 7.5% | 1.6% | 9.3% | 5.2% | 5.2% |
| Free cash flow margin | 5.7% | 1.3% | 1.2% | 9.1% | 1.9% | −0.7% | −0.7% | 12.7% | 2.5% | 3.9% |
| Rule of 40 (growth + FCF margin) | 19.1% | 6.1% | 6.4% | 12.9% | 17.1% | 10.3% | 5.8% | 11.4% | 4.0% | 4.9% |
| Return on capital | 9.4% | 6.3% | 7.2% | 8.3% | 10.5% | 11.3% | 4.6% | 9.0% | 10.3% | 9.4% |
| Return on equity | 13.1% | 8.4% | 9.0% | 10.2% | 13.7% | 19.5% | 3.9% | 20.1% | 9.8% | 9.1% |
| Return on assets | 6.8% | 3.9% | 4.1% | 5.0% | 6.7% | 10.0% | 2.0% | 11.3% | 6.4% | 6.1% |
| Net debt to EBITDA | 2.5x | 3.2x | 3.4x | 2.2x | 2.3x | 1.7x | 4.0x | 0.5x | 0.6x | 0.4x |